Jing Chen

Dr. Jing Chen


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JCJing Chen
Jing Chen
WWWenqing Wang
Wenqing Wang
CSChunyang Shi
Chunyang Shi
JFJianguo Fang
Jianguo Fang
Houttuynia cordata Thunb. (H. cordata) is an anti-inflammatory herbal drug that is clinically used in Asia. The essential oil obtained from H. cordata is known to contain 2-undecanone (2-methyl nonyl ketone). In addition, sodium houttuyfonate is a compound that can be derived from H. cordata and has important clinical uses as an anti-inflammatory agent. Sodium houttuyfonate can be converted to decanoyl acetaldehyde (houttuynin) and then to 2-undecanone. Therefore, the experiments described here explore the comparative anti-inflammatory activities of these compounds. Sodium houttuyfonate showed more potent anti-inflammatory activities than that of 2-undecanone at the same dosage, both in vitro and in vivo, although both compounds significantly inhibited the production of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and the expression of toll-like receptor 4 (TLR4), but increased the secretion of interleukin-10 (IL-10) in lipopolysaccharide (LPS)-stimulated RAW264.7 cells. In addition, both compounds showed dose-dependent inhibitory effects on xylene-induced mouse ear edema. In a previous study, we found sodium houttuyfonate to be transformed to 2-undecanone during steam distillation (SD). Optimum therapeutic effects are related to the stability and pharmacological activity of the drugs. Consequently, we studied the stability of sodium houttuyfonate under a simulated gastrointestinal environment with the main influencing factors being solvent, temperature and pH effects. For the first time, sodium houttuyfonate and 2-undecanone were detected simultaneously in the mouse serum and the gastrointestinal tissue after oral administration. Sodium houttuyfonate is detected within a short period of time in the systemic circulation and tissues without conversion to 2-undecanone.

11 August 2023 in BMC Cancer
Verified
Journal Article
Open access
PDF file
QZQilin Zhang
Qilin Zhang
YDYiling Ding
Yiling Ding
YSYamin Shu
Yamin Shu
JCJing Chen
Jing Chen
Background: Rucaparib has been approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. However, the long-term safety of rucaparib in large sample population was unknown. The presented study aimed to evaluate rucaparib-associated adverse events (AEs) according to the real-world pharmacovigilance database. Methods: Disproportionality analysis was conducted to assess the association between rucaparib and its AEs. Data were collected from the international pharmacovigilance database of US FDA Adverse Event Reporting System (FAERS) between January 2017 and June 2022. The characteristics of rucaparib-related AEs, and the onset time were further analyzed. Results: A total of 9,296,694 AE reports were recorded in the FAERS during the study period, among which 7,087 reports were associated with rucaparib. About 135 rucaparib-related AE signals in 15 system organ class (SOCs) were identified. The most common AEs included anaemia, thrombocytopenia, nausea, vomiting, fatigue, blood creatinine increase, alanine aminotransferase increase, and aspartate aminotransferase increase, which were listed in the label for rucaparib. Of note, 21 new and unexpected significant AEs that off-label were also found in our study, such as preferred term (PTs) of intestinal obstruction, gastrooesophageal reflux disease, blood iron decreased, dehydration, and hypersomnia. The median onset time of rucaparib-related AEs was 12 days (interquartile range [IQR] 1–62 days), and had early failure types. Conclusion: Our study demonstrated potential new AEs of rucaparib, and further studies were expected to confirm the results.


26 April 2024 in Heliyon
Verified
Journal Article
Open access
YDYiling Ding
Yiling Ding
HSHongyan Su
Hongyan Su
YSYamin Shu
Yamin Shu
JCJing Chen
Jing Chen
Sotorasib has been approved for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Due to the limitations of clinical trials, potential adverse events (AEs) and long-term safety issues cannot be detected. The presented study aimed to evaluate sotorasib-associated AEs using the FDA Adverse Event Reporting System (FAERS) database. Post-marketing AE reports of sotorasib in the database were collected for analysis. Disproportionality analyses, including the reporting odds ratio (ROR), proportional reporting ratio (PRR), information component (IC) and empirical bayes geometric mean (EBGM) algorithms, were performed to mine the signals of sotorasib-associated AEs. The median duration, quartiles and the Weibull shape parameter (WSP) test were used to assess the onset time data. The database contained 1538 cases of sotorasib as primary suspect (PS), with 27 signals detected, scattering in 5 SOCs. The SOC of hepatobiliary disorders (182, ROR 4.48, PRR 4.07, IC 2.02, EBGM 4.07) met the four methodological thresholds. The median onset time of sotorasib-associated AEs was 42 days (interquartile range [IQR] 14–86.75 days). Different SOCs had different types of risk over time. After obtaining marketing authorization, the study identified all potentially relevant adverse event (AE) signals expected to have a reporting frequency higher than anticipated and characterized them during sotorasib treatment.

1 August 2019
Verified
Conference Paper
Closed access
GLG.H. Li
G.H. Li
SLS.C. Liu
S.C. Liu
AKAng Ke
Ang Ke
XZX.F. Zhang
X.F. Zhang
JCJing Chen
Jing Chen
SWS.R. Wang
S.R. Wang
To mimic the nature stretch of axon, we developed a multiple channel device which can apply mechanical stretch to the neural axon. This device with four cell culture chambers and adjustable speed, which could be used to screening the stretch speed parameters and the potential nutrition factors that could be used to facilitate the regeneration of neuron fibers in vitro. The current design can range from 0.25um (min) to 50um (max) for each step, which covers the physiological and pathological stretch speed. The increased samples and the stepping ranges allow sophisticated experiments could be performed with this new device. The system compositions including structures and each module function are introduced in detail and the performance of this device is tested. The test of cell viability of this culture chamber show that the neuron cell and Schwann cells (SC) sustain normal morphology and cell viability. Axons stimulated by the mechanical stretch for 5 days at the speed of 1mm/day was tested by this system. The results showed that axon growth was promoted by mechanically stretch. The multi-channel axon-stretch device has been approved to be functionally in to culture neurons and stretch axons in one direction.